OR WAIT null SECS
Check out the latest features and columns!
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future
January's Executive Profile features CEO of Sumitovant Biopharma, Myrtle Potter
Pharm Exec's 17th Annual Pipeline Report focuses on Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic
Chief commercial officers gather for an insightful roundtable discussion anchored in the future of sales and marketing in light of new communication media brought on by the pandemic
How can clinical trials be designed to best study therapies for treating long COVID?
Highlighted Videos
January 26, 2022
New technology serves as reminder for the appropriate uses of CRISPR.
Uncertainty over experimental medicines calls for review of AA process.
January 24, 2022
International collaboration needed to address distribution hurdles.
Ariel Katz, CEO and co-founder of H1, talks about how to find the right KOL for the right audience at the right time.
Funding brings total investment to $123 million.
January 23, 2022
How digital is helping companies increase call volumes, access to HCPs, and HCP-led dialogue.
January 20, 2022
Providing ultimate value to stakeholders remains key in new style of development.
Indegene’s 2021–22 survey on the digital habits of HCPs across major regions provides some answers to pharma marketers looking to boost their post-pandemic physician engagement campaigns.
Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.
January 19, 2022
AI has the potential to revolutionize the pharma marketing industry. Pharma should look to harness its power to capture important data and insights to better engage HCPs through personalized, smart messaging.
